Mauricio Ferri

About Mauricio Ferri

Physician and pharmaceutical industry leader with extensive experience in strategic evidence generation for value communication in Medical Affairs and HEOR. Built and leads the CV HEOR/Value Demonstration Team supporting one of the most successful brands in the industry with a sharp focus on real-world evidence throughout the life cycle (Eliquis). Health services researcher with deep knowledge of scientific methods, clinical trials and real-world evidence ecosystem for cardiovascular rare diseases in the US with a proven track-record of scientific accomplishments as a senior leader in industry.Areas of Expertise- Experience in HEOR, Medical Affairs and Drug Development - Management of Complex Alliances and Internal Matrix - Evidence for Value Strategic Planning - Launch Preparedness and Excellence for Rare Cardiovascular Diseases- IRA Preparedness and Health Policy ImpactCurrent position:Executive Director – Cardiovascular Lead, US HEOR - 2021-PresentBuild and lead the CV US HEOR team focusing on evidence generation for Eliquis, Camzyos and earlier assets in CV. Drive and enable team excellence in execution, supporting key RWD studies, health economics and patient reported outcomes (PRO). Innovative scientific communication projects to address IRA negotiations, ICER reviews and impactful customer interactions. Staff: One Senior Director, three Directors, one PharmD Fellow- Support Clinical Development Team using RWD to optimize site selection and facilitate patient enrollment in phase and IV clinical trials- Innovative evidence generation: projects focusing on practice transformation in anticoagulation and HCM- Launch first-in-class myosin inhibitor (Camzyos) for obstructive hypertrophic cardiomyopathy in the US market with extensive PRO evidence-base included in the US PI.Other experiences:Medical affairs and HEOR at BMS since 2017.Before joining BMS in 2017, I worked as a consultant for the Guideline Review Committee Secretariat at WHO headquarters in Geneva developing methods and procedures for \"Ultra-Fast\" guideline production in response to public health emergencies. I contributed to the 2014-15 WHO Ebola Outbreak Response as a clinician, health services researcher, and trainer for the Clinical Management Team in Kenema and Freetown - Sierra Leone, and with the University of Oxford - RAPIDE-TKM-Ebola as a Trial Clinical Lead.

Experience

1. Senior Director, Research Strategy, Cvr

   Bayer

   Sep 2024 — Present · Whippany, NJ, US

Education

• University of Calgary

  International Clinical Fellowship, Critical Care Medicine

  2010 — 2013

• University of Calgary

  Certificate, Patient Safety and Quality Improvement

  2010 — 2011

• Universidade Federal do Paraná

  MD, Medical School

  1994 — 2000

• Massachusetts Institute of Technology

  Artificial Intelligent in Pharma and Biotech

• Universidade Estadual de Maringá

  Medical Residency, Internal Medicine

  2001 — 2003

• The Johns Hopkins University School of Medicine

  Lean Sigma Green Belt Course

  2012

• Hospital Israelita Albert Einstein

  Medical Residency, Critical Care Medicine

  2004 — 2006

• University of Toronto

  Clinical Fellowship, Sunnybrook HSC, Department of Critical Care

  2006 — 2009

• University of Calgary

  Master's of Science - Department of Community Health Sciences, Health Services Research

  2011 — 2015

Skills

• Patient Safety
• Health Economics
• Healthcare Design
• Intensive Care
• Stata
• Cardiovascular Icu
• Qualitative Research
• Lean Sigma
• Hospitals
• Critical Care Medicine
• Medical Education
• Six Sigma
• Internal Medicine
• Public Health
• Healthcare
• Healthcare Management
• Nvivo
• Medicine
• Icu
• Critical Care
• Clinical Research
• Clinical Trials
• Quality Improvement